EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene Variant Frequencies of IDO1, IDO2, TDO, and KMO in Substance Use Disorder Cohorts

Lindsey Contella iD, Christopher L Farrell iD, Luigi Boccuto iD, Alain Litwin, Marion L Snyder

Genes · 2024

DOI: 10.3390/genes15111388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Lindsey Contella und 4 weiteren Autor:innen. Beteiligte Einrichtung: Healthcare Genetics and Genomics, School of Nursing, Clemson University, 605 Grove Rd., Greenville, SC 29605, USA. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Substance-Related Disorders, Tryptophan Oxygenase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Substance use disorder in the United States represents a complex and growing public health crisis, marked by increasing rates of overdose deaths and the misuse of prescription medications. There is a critical need for furthering the understanding of the molecular and genetic mechanisms that can lead to substance use disorder. Identifying significant variants in the kynurenine pathway could help identify therapeutic targets for intervention.

Methods

The All of Us cohort builder evaluated the frequency of variants of four genes, TDO2, IDO1, IDO2, and KMO, encoding enzymes in the kynurenine pathway. The samples were broken into six cohorts: alcohol, cannabis, cocaine, opioid, other use disorder, and control. Using Chi-square analysis, the frequency of at least one copy of a variant allele was calculated.

Results

Chi-square analysis showed a significant variation in genetic frequency (p-value < 0.005) in 14 of 18 polymorphisms analyzed. The cocaine cohort had the most significant variants (13), cannabis had 11, opioids had 3, other use disorders had 2, and alcohol had 1 significant variant.

Conclusions

This study found associations of polymorphisms in the TDO2, IDO1, IDO2, and KMO genes of individuals with a substance use disorder. These results provide evidence of potential predictors of increased susceptibility to substance use disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Indoleamine-Pyrrole 2,3,-DioxygenaseSubstance-Related DisordersTryptophan OxygenaseHumansGene FrequencyMaleKynurenine 3-MonooxygenaseFemaleCohort StudiesAdultGenetic Predisposition to DiseaseKynureninePolymorphism, Single Nucleotide

Stichwörter der Autor:innen

genetic frequencykynurenine pathwaysubstance use disordertryptophan

Substanzen

Indoleamine-Pyrrole 2,3,-DioxygenaseIDO1 protein, humanIDO2 protein, humanTryptophan OxygenaseKynurenine 3-MonooxygenaseKynurenine

Autor:innen und Institutionen

  • Healthcare Genetics and Genomics, School of Nursing, Clemson University, 605 Grove Rd., Greenville, SC 29605, USA.
  • Luxor Scientific, LLC, 1327 Miller Rd., Greenville, SC 29607, USA.
  • School of Health Research, Clemson University, Clemson, SC 29631, USA.
  • Department of Medicine, Prisma Health, 701 Grove Rd., Greenville, SC 29605, USA.
  • Department of Medicine, University of South Carolina School of Medicine, 876 W Faris Rd., Greenville, SC 29605, USA.

ORCID-Profile: Lindsey Contella, Christopher L Farrell, Luigi Boccuto

Zitieren

APA

Contella, L., Farrell, C. L., Boccuto, L., Litwin, A., & Snyder, M. L. (2024). Gene Variant Frequencies of IDO1, IDO2, TDO, and KMO in Substance Use Disorder Cohorts. Genes. https://doi.org/10.3390/genes15111388

Vancouver

Contella L, Farrell CL, Boccuto L, Litwin A, Snyder ML. Gene Variant Frequencies of IDO1, IDO2, TDO, and KMO in Substance Use Disorder Cohorts. Genes. 2024. doi:10.3390/genes15111388

BibTeX
@article{Contella2024,
  author = {Contella, Lindsey and Farrell, Christopher L and Boccuto, Luigi and Litwin, Alain and Snyder, Marion L},
  title = {Gene Variant Frequencies of IDO1, IDO2, TDO, and KMO in Substance Use Disorder Cohorts},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15111388}
}
Kostenlos starten →